News Release

Company name: H.U. Group Holdings, Inc.
Representative: Goki Ishikawa, Representative Executive Officer, President and Group CEO
Securities code: 4544 Prime Market, Tokyo Stock Exchange

Fujirebio Receives Technology Award from the Japan Society of Clinical Chemistry – Eighth Award in the Past 10 Years –

Tokyo, Japan, October 5, 2026 --- H.U. Group Holdings, Inc. today announced that its wholly owned subsidiary Fujirebio has received the Technology Award from the Japan Society of Clinical Chemistry.

The award recognizes achievements in research and development in the field of clinical chemistry, significant improvements to existing products, and the discovery of new applications that create added value. Fujirebio received the award for its work on the Lumipulse™ Presto iTACT™ HBcrAg assay.*

This is the eighth time Fujirebio has received the award in the past 10 years. As a leading company in the in vitro diagnostics industry, Fujirebio has long been developing testing solutions for a wide range of platforms. These repeated honors, including this latest award, reflect the company's sustained commitment to research and development.

Fujirebio will continue to draw on its technological expertise and accumulated knowledge to create new value in the in vitro diagnostics industry and contribute to people's health and the advancement of healthcare through diagnostic testing.

* An in vitro diagnostic test for measuring hepatitis B virus core-related antigen (HBcrAg) in serum or plasma. Fujirebio's proprietary iTACT technology, which stands for Immunoassay for Total Antigen including Complex via pre-Treatment, enables automated sample pretreatment and highly sensitive measurement. This reagent is for the Japanese market only and is not sold outside Japan.

【About H.U. Group】

H.U. Group was founded in 1950 and is headquartered in Tokyo, Japan. The company provides essential healthcare products and services worldwide and employs more than 10,000 people across the United States, Europe, and Japan. H.U. Group Holdings, Inc. (TSE: 4544) operates a diverse healthcare portfolio that includes Fujirebio, a global diagnostics company; SRL, one of Japan's leading clinical laboratory testing providers; and Nihon Stery, a specialist in medical sterilization services. Leveraging the strengths of its core businesses, H.U. Group advances its "Group Strategy by Disease Area" centered on the Patient Journey, with a particular focus on areas such as Oncology and NEURO.

In the field of *in vitro* diagnostics (IVD), Fujirebio delivers innovative, high-impact solutions worldwide, including the first FDA-cleared blood-based IVD test to aid in the diagnosis of Alzheimer's disease. The company also offers a flexible CDMO model to diagnostic partners. In clinical laboratory testing and healthcare support services, SRL and Nihon Stery support healthcare providers throughout Japan, leveraging strong relationships with major medical institutions nationwide.

Guided by its mission to "create new value in healthcare and thereby contribute to human health and the future of medical care", H.U. Group leverages innovation and partnerships to address unmet medical needs and realize its vision of becoming "a GLOBAL H.U. Group". For more information, please visit https://www.hugp.com/en/.

Contacts:

For media:

Public Relations Section, Public Relations/Sustainability Dept.

Phone: +81-3-6279-0884
Email: pr@hugp.com

For investors and analysts:

IR/SR Dept.

Phone: +81-3-6279-0926
Email: ir@hugp.com